Abstract:Objective:To explore the effect of the acute treatment outcome on the trajectory of residual symptoms for major depressive disorder (MDD).Method:This is a multicenter, prospective, non-intervention study. The MDD patients who self-reported an improvement after received an 8-12 weeks antidepressant treatment were included. Social-demographic and clinical characteristics were collected at the baseline. Brief 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR 16), Generalized Anxiety Disorder Scale (GAD-7), Arizona Sexual Experience Scale experience (ASEX), Digital Span Test (DST) and Digit Symbol Substitution Test (DSST) were used to assess the symptoms. Patients were followed up at month 1, 3 and 6. Mix effect model and generalized estimating equation were used to analysis changes over visits of symptoms within or between groups. Result:Totally, 428 eligible patients were included in this study. At baseline, 179 patients achieved remission (41.8%,179/428) and 249 achieved partial remission (58.2%,249/428). There were no significant differences in demographics, clinical characteristics and treatment between the two groups. The proportion of increased appetite, weight gain, suicidal ideation, and restlessness in the remission group did not change significantly over time ( Z=-1.62-1.34, all P>0.003), meanwhile, the proportion of hypersomnia, increased appetite, and weight gain in the partial remission group did not change significantly over the course of the assessments ( Z=-2.43- -1.26, all P>0.003). The proportion of other residual symptoms changed significantly from baseline to 6-month follow-up in both groups ( Z=-10.77- -2.46, all P<0.003), nevertheless, there was no significant difference between the two groups ( Z=0.37-3.26, all P>0.003). The total score of GAD-7 of the two groups were significantly different at each assessment timepoint (χ 2=24.68-113.80, P<0.01), and the improvement of anxiety in the remission group was better than that in the partial remission group ( F=8.39, P<0.01). There were no significant differences in the total ASEX scores between the two groups at each visit ( F=-1.93- -0.68, all P>0.05), and there were no significant difference within the group ( F=0.01-0.17, P>0.05). There was no significant difference in the total scores of DST and DSST between the two groups at baseline ( F=-1.23, -1.14, all P>0.05), and also no significant differences were found during all follow-up visits after control for score at baseline ( F=-1.14- -0.91, all P>0.05). Conclusions:The treatment outcome of the acute phase has an impact on the residual symptoms of MDD. Remission has a positive effect on the improvement of anxiety, but has no significant effect on the improvement of sexual dysfunction and cognitive function.

Factor analysis of target symptoms of amitriptyline in the treatment of endogenous depression

Comparative Study of Citalopram and Amitriptyline in the Treatment of Depression

Efficacy of fluoxetine combined with psychological intervention for treatment of depressive patients with insomnia

Meta-analysis of Differences on Incidence of Dry Mouth,insomnia and Anxiety Induced by Venlafaxine and Tricyclic Antidepressants in the Treatment of Depression in Domestic Index

Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression

The network analysis of depressive symptoms before and after two weeks of antidepressant treatment

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine

Comparison of the Effectiveness of Duloxetine in Depressed Patients with and Without a Family History of Affective Disorders in First-Degree Relatives.

Evaluation of clinical efficacy about different ways treating major depressive disorder

The characteristics of sympathetic skin response in patients with depression

Comparative Study of Citalopram and Amitriptyline in the Treatment of High School Students and Undergraduates' Depression

Antidepressant Treatment Strategy with an Early Onset of Action Improves the Clinical Outcome in Patients with Major Depressive Disorder and High Anxiety: a Multicenter and 6-Week Follow-Up Study

Efficacy of Escitalopram Monotherapy in the Treatment of Major Depressive Disorder

Effects of treatment outcome in acute phase of depression on residual symptoms in a 6-month follow-up: a national, multicenter study

Control study of mirtazapine and fluoxetine in therapy of depression

LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients--a controlled 6-week clinical trial

An Analysis on the Cognitive Function in Depression Before and after Therapy

Comparative studty of the drug treatment in depressive patients with anxious or insomnia symptoms

Effects of chronotype on antidepressant treatment and symptoms in patients with depression: a multicenter, parallel, controlled study

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.

Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study